The Effect of Remote Ischemic Postconditioning on Quality of Life and Clinical Events after an Ischemic Stroke

Author:

Kerstens Thijs P.1,Landman Thijs R.J.1,Schoon Yvonne2,Meijer Frederick J.A.3,Warlé Michiel C.4,de Leeuw Frank-Erik5,Thijssen Dick H.J.1

Affiliation:

1. Department of Medical BioSciences, Radboud University Nijmegan Medical Center, Geert Grooteplein Zuid 10, Nijmegen, Gelderland, Netherlands, 6525GA

2. Department of Geriatric Medicine, Radboud University Nijmegan Medical Center, Radboud Institute for Health sciences, Geert Grooteplein Zuid 10, Nijmegen, Gelderland, Netherlands, 6525GA

3. Department of Medical Imaging, Radboud University Nijmegan Medical Center, Geert Grooteplein Zuid 10, Nijmegen, Gelderland, Netherlands, 6525GA

4. Department of Surgery, Radboud University Nijmegan Medical Center, Geert Grooteplein Zuid 10, Nijmegen, Gelderland, Netherlands, 6525GA

5. Department of Neurology, Radboud University Nijmegan Medical Center, Donders Center for Medical Neuroscience PO Box 9101, 6500HB Nijmegen

Abstract

Objectives: Repeated remote ischemic postconditioning (rIPostC) may be an easily applicable treatment following ischemic stroke to improve quality of life (QoL) and clinical outcomes. rIPostC consists of repeated, brief periods of limb ischemia (through inflation of a blood pressure cuff), followed by reperfusion. This study investigated the 1-year follow-up of rIPostC on QoL and clinical events. Methods: As part of a randomized controlled trial, adult patients with an ischemic stroke within 24 hours after onset of symptoms were randomized to repeated rIPostC or sham-conditioning. rIPostC was applied twice daily during hospitalization (maximum of 4 days). QoL and patientreported outcome measures (PROMs) were assessed at 12-week and 1-year follow-ups. Additionally, we explored the effect of repeated rIPostC on clinical events (recurrent cerebrovascular events, hospitalization, and mortality). Results: The trial was preliminarily stopped due to limitations in recruitment after the inclusion of 88 patients (rIPostC: 40; sham-conditioning: 48) (70 years, 68% male). Questionnaires were returned by 69 (78%) and 63 (72%) participants after 12 weeks and 1 year, respectively. The median difference of the stroke-specific QoL between rIPostC and sham-conditioning was 0.05 (p =0.986) and -0.16 (p =0.654) after 12 weeks and 1-year, respectively. No significant effect of rIPostC on the different domains of PROMs was detected. We observed no between-group differences in recurrent cerebrovascular events, hospitalization, or all-cause mortality (Hazard Ratios p >0.05). Conclusion: In this exploratory analysis, we observed no significant difference between repeated rIPostC and usual care on QoL and clinical outcomes at 12 weeks and 1 year in patients with an ischemic stroke. Clinical Trial Registration Number: NTR6880.

Publisher

Bentham Science Publishers Ltd.

Subject

Cellular and Molecular Neuroscience,Developmental Neuroscience,Neurology,Neurology (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3